The TETON-2 study met its primary endpoint, showing a 95.6 mL benefit in absolute FVC over placebo at week 52 (p<0.0001). How meaningful is this improvement in slowing IPF progression, given the chronic and degenerative nature of the disease?

Positive efficacy signals were observed across all prespecified subgroups, including patients on antifibrotic background therapy, those not receiving treatment, and patients using supplemental oxygen. How important is this consistency for broad clinical adoption of Tyvaso?

Several secondary endpoints, including time to clinical worsening, percent predicted FVC, DLCO, and K-BILD quality-of-life scores, showed statistically significant benefits. Which of these findings do you find most clinically compelling, and why?

Patients receiving Tyvaso demonstrated improvements in K-BILD scores, which measure health-related quality of life in IPF. How valuable are these improvements when evaluating new therapies, especially for patients already on standard antifibrotic treatments?

Currently approved antifibrotics, such as nintedanib and pirfenidone, often offer modest benefits and can be limited by tolerability issues. Where does inhaled Tyvaso potentially fit within the evolving IPF treatment paradigm, particularly as an add-on or alternative therapy?

The TETON-2 trial reported no new safety signals, with adverse events consistent with prior Tyvaso studies and prostacyclin-related effects. How do these safety outcomes influence your comfort level with long-term use of inhaled Tyvaso in IPF patients?

United Therapeutics plans to use TETON-2 data alongside the ongoing TETON-1 trial to support a supplemental NDA for Tyvaso in IPF. What are your expectations for regulatory review, and how might an approval reshape treatment options for this underserved patient population?

Given Tyvaso’s success in pulmonary hypertension associated with interstitial lung disease and now IPF, do you anticipate its role expanding further across other fibrotic lung conditions? What additional studies would you like to see to validate its broader utility?